Argent Capital Management LLC Has $57.96 Million Stake in Boston Scientific Corporation (BSX)

Argent Capital Management LLC trimmed its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 1.8% in the second quarter, according to its most recent filing with the SEC. The firm owned 2,090,720 shares of the medical equipment provider’s stock after selling 39,090 shares during the period. Boston Scientific Corporation makes up about 2.3% of Argent Capital Management LLC’s investment portfolio, making the stock its 15th biggest position. Argent Capital Management LLC owned 0.15% of Boston Scientific Corporation worth $57,955,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Guardian Life Insurance Co. of America lifted its holdings in shares of Boston Scientific Corporation by 0.9% during the 1st quarter. Guardian Life Insurance Co. of America now owns 5,266 shares of the medical equipment provider’s stock worth $131,000 after acquiring an additional 49 shares during the period. Acrospire Investment Management LLC lifted its holdings in shares of Boston Scientific Corporation by 157.3% during the 2nd quarter. Acrospire Investment Management LLC now owns 5,071 shares of the medical equipment provider’s stock worth $141,000 after acquiring an additional 3,100 shares during the period. Bronfman E.L. Rothschild L.P. lifted its holdings in shares of Boston Scientific Corporation by 14.3% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 5,761 shares of the medical equipment provider’s stock worth $160,000 after acquiring an additional 720 shares during the period. San Francisco Sentry Investment Group CA bought a new position in shares of Boston Scientific Corporation during the 2nd quarter worth about $191,000. Finally, Peddock Capital Advisors LLC bought a new position in shares of Boston Scientific Corporation during the 2nd quarter worth about $201,000. 90.44% of the stock is owned by institutional investors.

Boston Scientific Corporation (NYSE BSX) traded up 0.24% during midday trading on Friday, reaching $29.50. 4,980,172 shares of the company’s stock traded hands. Boston Scientific Corporation has a 52-week low of $19.67 and a 52-week high of $29.54. The company has a market cap of $40.48 billion, a P/E ratio of 52.77 and a beta of 1.09. The stock has a 50-day moving average of $28.30 and a 200 day moving average of $26.99.

Boston Scientific Corporation (NYSE:BSX) last posted its earnings results on Thursday, July 27th. The medical equipment provider reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.01. The firm had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.21 billion. Boston Scientific Corporation had a net margin of 9.04% and a return on equity of 23.62%. The business’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.27 earnings per share. On average, analysts anticipate that Boston Scientific Corporation will post $1.26 earnings per share for the current fiscal year.

BSX has been the subject of a number of analyst reports. Royal Bank Of Canada reaffirmed a “buy” rating and set a $31.00 price objective on shares of Boston Scientific Corporation in a report on Wednesday, July 12th. BidaskClub downgraded shares of Boston Scientific Corporation from a “strong-buy” rating to a “buy” rating in a report on Thursday, July 6th. Needham & Company LLC lifted their price target on shares of Boston Scientific Corporation from $30.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, June 22nd. BMO Capital Markets reissued a “buy” rating and set a $30.00 price target on shares of Boston Scientific Corporation in a report on Wednesday, June 21st. Finally, Cowen and Company reissued a “buy” rating and set a $32.00 price target (up from $31.00) on shares of Boston Scientific Corporation in a report on Friday, July 28th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. Boston Scientific Corporation currently has a consensus rating of “Buy” and an average target price of $30.13.

In other news, EVP Supratim Bose sold 347,137 shares of the stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $29.12, for a total value of $10,108,629.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Timothy A. Pratt sold 11,061 shares of the stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $29.24, for a total transaction of $323,423.64. Following the completion of the transaction, the executive vice president now directly owns 174,681 shares of the company’s stock, valued at approximately $5,107,672.44. The disclosure for this sale can be found here. Insiders sold 623,455 shares of company stock valued at $17,676,597 in the last three months. Company insiders own 0.74% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This article was originally posted by The Ledger Gazette and is the sole prop

Other large investors have also added to or reduced their stakes in the company. Guardian Life Insurance Co. of America lifted its holdings in shares of Boston Scientific Corporation by 0.9% during the 1st quarter. Guardian Life Insurance Co. of America now owns 5,266 shares of the medical equipment provider’s stock worth $131,000 after acquiring an additional 49 shares during the period. Acrospire Investment Management LLC lifted its holdings in shares of Boston Scientific Corporation by 157.3% during the 2nd quarter. Acrospire Investment Management LLC now owns 5,071 shares of the medical equipment provider’s stock worth $141,000 after acquiring an additional 3,100 shares during the period. Bronfman E.L. Rothschild L.P. lifted its holdings in shares of Boston Scientific Corporation by 14.3% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 5,761 shares of the medical equipment provider’s stock worth $160,000 after acquiring an additional 720 shares during the period. San Francisco Sentry Investment Group CA bought a new position in shares of Boston Scientific Corporation during the 2nd quarter worth about $191,000. Finally, Peddock Capital Advisors LLC bought a new position in shares of Boston Scientific Corporation during the 2nd quarter worth about $201,000. 90.44% of the stock is owned by institutional investors.

Boston Scientific Corporation (NYSE BSX) traded up 0.24% during midday trading on Friday, reaching $29.50. 4,980,172 shares of the company’s stock traded hands. Boston Scientific Corporation has a 52-week low of $19.67 and a 52-week high of $29.54. The company has a market cap of $40.48 billion, a P/E ratio of 52.77 and a beta of 1.09. The stock has a 50-day moving average of $28.30 and a 200 day moving average of $26.99.

Boston Scientific Corporation (NYSE:BSX) last posted its earnings results on Thursday, July 27th. The medical equipment provider reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.01. The firm had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.21 billion. Boston Scientific Corporation had a net margin of 9.04% and a return on equity of 23.62%. The business’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.27 earnings per share. On average, analysts anticipate that Boston Scientific Corporation will post $1.26 earnings per share for the current fiscal year.

BSX has been the subject of a number of analyst reports. Royal Bank Of Canada reaffirmed a “buy” rating and set a $31.00 price objective on shares of Boston Scientific Corporation in a report on Wednesday, July 12th. BidaskClub downgraded shares of Boston Scientific Corporation from a “strong-buy” rating to a “buy” rating in a report on Thursday, July 6th. Needham & Company LLC lifted their price target on shares of Boston Scientific Corporation from $30.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, June 22nd. BMO Capital Markets reissued a “buy” rating and set a $30.00 price target on shares of Boston Scientific Corporation in a report on Wednesday, June 21st. Finally, Cowen and Company reissued a “buy” rating and set a $32.00 price target (up from $31.00) on shares of Boston Scientific Corporation in a report on Friday, July 28th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. Boston Scientific Corporation currently has a consensus rating of “Buy” and an average target price of $30.13.

In other news, EVP Supratim Bose sold 347,137 shares of the stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $29.12, for a total value of $10,108,629.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Timothy A. Pratt sold 11,061 shares of the stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $29.24, for a total transaction of $323,423.64. Following the completion of the transaction, the executive vice president now directly owns 174,681 shares of the company’s stock, valued at approximately $5,107,672.44. The disclosure for this sale can be found here. Insiders sold 623,455 shares of company stock valued at $17,676,597 in the last three months. Company insiders own 0.74% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This article was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://ledgergazette.com/2017/10/08/argent-capital-management-llc-has-57-96-million-stake-in-boston-scientific-corporation-bsx.html.

Boston Scientific Corporation Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply